UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2011
ANACOR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
001-34973 |
|
25-1854385 |
|
(State of incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
1020 East Meadow Circle
Palo Alto, CA 94303-4230
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 543-7500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On January 21, 2011, the Compensation Committee of Board of Directors of Anacor Pharmaceuticals, Inc. (the “Company”) determined that the cash incentive bonuses payable to certain of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission) under the Company’s 2010 cash incentive bonus plan, were as set forth in the table below, based on the achievement of corporate objectives for 2010 and individual objectives for such persons for the fourth quarter of 2010 established under such plan.
|
Named Executive Officer |
|
Cash Incentive Bonus (1) |
|
|
|
|
|
|
|
Geoffrey M. Parker, Senior Vice President, Chief Financial Officer |
|
$26,681 |
|
|
|
|
|
|
|
Kirk R. Maples, Ph.D., Senior Vice President, Program Management |
|
$67,005 |
|
|
|
|
|
|
|
Jacob J. Plattner, Ph.D., Senior Vice President, Research |
|
$70,910 |
|
|
|
|
|
|
|
Irwin A. Heyman, Ph.D., Senior Vice President, Product Development |
|
$55,470 |
|
(1) Based on the achievement of corporate objectives for 2010 and individual objectives for the fourth quarter of 2010
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: January 27, 2011 |
|
ANACOR PHARMACEUTICALS, INC. | |
|
|
|
|
|
|
|
|
By: |
/s/ Geoffrey M. Parker |
|
|
|
|
Geoffrey M. Parker |
|
|
|
|
Senior Vice President, Chief Financial Officer |